EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase II)Open Access · CC BY 4.0

Long‐term pharmacodynamic and clinical effects of twice‐ versus once‐daily low‐dose aspirin in essential thrombocythemia: The ARES trial

Bianca Rocca, Alberto Tosetto iD, Giovanna Petrucci, Elena Rossi, Silvia Betti, Denise Soldati, Alessandra Iurlo iD, Daniele Cattaneo, Cristina Bucelli, Alfredo Dragani, Mauro Di Ianni, Paola Ranalli und 18 weitere

American Journal of Hematology · 2024-08 · 99 (8) · 1462-1474

DOI: 10.1002/ajh.27418 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift American Journal of Hematology, online erschienen am 15.06.2024. Verfasst von Bianca Rocca und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Safety and Bioethics, Section of Pharmacology, Catholic University School of Medicine, Rome, Italy. Hauptthemen laut MEDLINE: Aspirin, Thrombocythemia, Essential, Platelet Aggregation Inhibitors, Drug Administration Schedule. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agenzia Italiana del Farmaco (AIFA), Ministero della Salute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with essential thrombocythemia (ET) are treated with once‐daily low‐dose aspirin to prevent thrombosis, but their accelerated platelet turnover shortens the antiplatelet effect. The short‐term Aspirin Regimens in EsSential Thrombocythemia trial showed that twice‐daily aspirin dosing restores persistent platelet thromboxane (TX) inhibition. However, the long‐term pharmacodynamic efficacy, safety and tolerability of twice‐daily aspirin remain untested. We performed a multicenter, randomized, open‐label, blinded‐endpoint, phase‐2 trial in which 242 patients with ET were randomized to 100 mg aspirin twice‐ or once‐daily and followed for 20 months. The primary endpoint was the persistence of low serum TXB 2 , a surrogate biomarker of antithrombotic efficacy. Secondary endpoints were major and clinically relevant non‐major bleedings, serious vascular events, symptom burden assessed by validated questionnaires, and in vivo platelet activation. Serum TXB 2 was consistently lower in the twice‐daily versus once‐daily regimen on 10 study visits over 20 months: median 3.9 ng/mL versus 19.2 ng/mL, respectively; p < .001; 80% median reduction; 95% CI, 74%–85%. No major bleeding occurred. Clinically relevant non‐major bleedings were non‐significantly higher (6.6% vs. 1.7%), and major thromboses lower (0.8% vs. 2.5%) in the twice‐daily versus once‐daily group. Patients on the twice‐daily regimen had significantly lower frequencies of disease‐specific symptoms and severe hand and foot microvascular pain. Upper gastrointestinal pain was comparable in the two arms. In vivo platelet activation was significantly reduced by the twice‐daily regimen. In patients with ET, twice‐daily was persistently superior to once‐daily low‐dose aspirin in suppressing thromboxane biosynthesis and reducing symptom burden, with no detectable excess of bleeding and gastrointestinal discomfort.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AspirinThrombocythemia, EssentialPlatelet Aggregation InhibitorsDrug Administration ScheduleHemorrhageHumansMaleMiddle AgedFemaleAgedAdultThromboxane B2Platelet ActivationAged, 80 and overTreatment Outcome

Substanzen

AspirinPlatelet Aggregation InhibitorsThromboxane B2

Autor:innen und Institutionen

  • Department of Safety and Bioethics, Section of Pharmacology, Catholic University School of Medicine, Rome, Italy.
  • Department NeuroFarBa, University of Florence, Florence, Italy.
  • Hematology Department, San Bortolo Hospital, Vicenza, Italy.
  • Department of Radiological and Hematological Sciences, Section of Hematology, Catholic University School of Medicine, Roma, Italy.
  • Fondazione Policlinico Universitario A. Gemelli, IRCCS, Roma, Italy.
  • Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy.

ORCID-Profile: Alberto Tosetto, Alessandra Iurlo, Marco Ruggeri, Elena Maria Elli, Maria Luigia Randi, Irene Bertozzi, Giuseppe Gaetano Loscocco, Alessandro M Vannucchi, Valerio De Stefano

Förderung

  • Agenzia Italiana del Farmaco (AIFA), Ministero della Salute

Zitieren

APA

Rocca, B., Tosetto, A., Petrucci, G., Rossi, E., Betti, S., Soldati, D., Iurlo, A., Cattaneo, D., Bucelli, C., Dragani, A., Di Ianni, M., Ranalli, P., Palandri, F., Vianelli, N., Beggiato, E., Lanzarone, G., Ruggeri, M., Carli, G., Elli, E. M., …, & Aspirin Regimens in EsSential thrombocythemia (ARES) Investigators (2024). Long‐term pharmacodynamic and clinical effects of twice‐ versus once‐daily low‐dose aspirin in essential thrombocythemia: The ARES trial. American Journal of Hematology, 99(8), 1462-1474. https://doi.org/10.1002/ajh.27418

Vancouver

Rocca B, Tosetto A, Petrucci G, Rossi E, Betti S, Soldati D, et al. Long‐term pharmacodynamic and clinical effects of twice‐ versus once‐daily low‐dose aspirin in essential thrombocythemia: The ARES trial. American Journal of Hematology. 2024;99(8):1462-1474. doi:10.1002/ajh.27418

BibTeX
@article{Rocca2024,
  author = {Rocca, Bianca and Tosetto, Alberto and Petrucci, Giovanna and Rossi, Elena and Betti, Silvia and Soldati, Denise and Iurlo, Alessandra and Cattaneo, Daniele and Bucelli, Cristina and Dragani, Alfredo and Di Ianni, Mauro and Ranalli, Paola and Palandri, Francesca and Vianelli, Nicola and Beggiato, Eloise and Lanzarone, Giuseppe and Ruggeri, Marco and Carli, Giuseppe and Elli, Elena Maria and Renso, Rossella and Randi, Maria Luigia and Bertozzi, Irene and Loscocco, Giuseppe Gaetano and Ricco, Alessandra and Specchia, Giorgina and Vannucchi, Alessandro M and Rodeghiero, Francesco and De Stefano, Valerio and Patrono, Carlo and Aspirin Regimens in EsSential thrombocythemia (ARES) Investigators, Aspirin Regimens in EsSential thrombocythemia (ARES) Investigators},
  title = {Long‐term pharmacodynamic and clinical effects of twice‐ versus once‐daily low‐dose aspirin in essential thrombocythemia: The ARES trial},
  journal = {American Journal of Hematology},
  year = {2024},
  volume = {99},
  number = {8},
  pages = {1462--1474},
  doi = {10.1002/ajh.27418}
}
Kostenlos starten →